MSB (ASX) Mesoblast stock(rock)-take March 2024

Originally posted by stockrock: ↑

Below is how the FDA defines a Class 1 resubmission... and why some are suggesting a 2 month review.

Class 1 Resubmission — A resubmission that includes one or more of the following items:

1. Final printed labeling

2. Draft labeling

3. Safety updates submitted in the same format, including tabulations, as the original safety submission with new data and changes highlighted (except
when large amounts of new information, including important new adverse experiences, not previously reported with the product are presented in the resubmission)

4. Stability updates to support provisional or final dating periods

5. Discussions of postmarketing requirements/commitments, including proposals or protocols for such requirements/commitments

6. Assay validation data

7. Final release testing on the last 1 to 2 lots used to support approval

8. A minor re-analysis of data previously submitted to the application (determined by CDER as fitting the Class 1 category)

9. Other minor clarifying information (determined by CDER as fitting the Class 1 category)

In addition, here is a brief side by side comparison FDA draft guidance on the topic of "Meeting the substantial evidence standard based on one adequate and well controlled clinical investigation plus confirmatory evidence"
of confirmatory evidence "Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products"
Dec19 FDA Draft Guidance "Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence"
Sep23 FDA Draft Guidance, which complements the Dec19 FDA Draft Guidance
1 Adequate and well-controlled clinical investigations in a related disease area Yes Yes
2 Certain types of real world evidence, such as extensive data on outcomes that provide further support for the lack of effect seen in the control group in the randomised trial Yes Yes
3 Compelling mechanistic evidence in the setting of a well-understood disease pathophysiology Yes Yes
4 Well-documented natural history of disease Yes Yes
5 Evidence from a relevant animal model Not mentioned Yes
6 Evidence from other members of the same pharmacological class Yes Yes
7 Evidence from Expanded Access Use Not mentioned Yes
8

Where Mesoblast were trying to present EAP data in the past to demonstrate both the mechanism of action, as well as efficacy, the FDA essentially ignored it due to "confounding factors" and did not treat is as confirmatory clinical evidence.

This is dispite the 240+ patient data submitted back in 2020, and likely many more by now ... all of this was essentially ignored by the FDA.

Fast forward to September 2023, and all the EAP data submitted by MSB suddenly became acceptable confirmatory trial data, provided that the FDA deemed it to be of sufficient quantity and quality... the status of this data may well have been elevated overnight from 'junk status' to 'treasury trove of clinical evidence' .

A subtle update by the FDA, which I believe has allowed the FDA to find the grounds it needed to accept Mesoblast's clinical data set provided to date.

goodluck all
Expand
IMO Mesoblast received a non-binding recommendation based on their confirmatory evidence.
Substantial holders topped up in recent months. Some holders won’t make it to 5% so it’s hard to gauge significant ownership.
Day traders have just about exited in this first run. SP is holding up really well tbh.
Shorts are taking a massive gamble at this stage. But that’s shorts for you.
I’m prepared to be patient.
P.S This document is a good read.
https://www.fda.gov/media/172166/download
My musings only. GLTA and Happy Friday

No.	Vol.	Price($)
1	15000	$1.19

No.

Vol.

Price($)

15000

$1.19

Price($)	Vol.	No.
$1.19	75212	5

Price($)

Vol.

No.

$1.19

75212

No.	Vol.	Price($)
1	15000	1.185
1	20000	1.175
1	5664	1.170
1	17568	1.160
3	56695	1.150

No.

Vol.

Price($)

15000

1.185

20000

1.175

5664

1.170

17568

1.160

56695

1.150

Price($)	Vol.	No.
1.190	59712	2
1.195	36255	5
1.200	404381	31
1.205	3000	1
1.210	162475	7

Price($)

Vol.

No.

1.190

59712

1.195

36255

1.200

404381

1.205

3000

1.210

162475

(20min delay)
Last $1.19		Change 0.085(7.69%)		Mkt cap ! $1.358B

Open	High	Low	Value	Volume
$1.10	$1.20	$1.09	$13.21M	11.37M

Mesoblast stock(rock)-take March 2024, page-127

Immutep reports strong response rate from immunotherapies treating carcinomas

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Almonty locks in govt agreement for tungsten oxide plant in South Korea

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Bitcoin investors need to know the risks

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

	of confirmatory evidence	"Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products" Dec19 FDA Draft Guidance	"Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence" Sep23 FDA Draft Guidance, which complements the Dec19 FDA Draft Guidance
1	Adequate and well-controlled clinical investigations in a related disease area	Yes	Yes
2	Certain types of real world evidence, such as extensive data on outcomes that provide further support for the lack of effect seen in the control group in the randomised trial	Yes	Yes
3	Compelling mechanistic evidence in the setting of a well-understood disease pathophysiology	Yes	Yes
4	Well-documented natural history of disease	Yes	Yes
5	Evidence from a relevant animal model	Not mentioned	Yes
6	Evidence from other members of the same pharmacological class	Yes	Yes
7	Evidence from Expanded Access Use	Not mentioned	Yes
8

Mesoblast stock(rock)-take March 2024, page-127

Top Stories

Immutep reports strong response rate from immunotherapies treating carcinomas

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Almonty locks in govt agreement for tungsten oxide plant in South Korea

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Bitcoin investors need to know the risks

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News